Viropharma

Lev Pharma wins FDA approval for Cinryze

John Carroll — Mon, 13 Oct 2008 11:31:14 -0400

Lev Pharmaceuticals has won FDA approval to market Cinryze to treat hereditary angioedema, a potentially lethal genetic disorder characterized by a swelling of the hands, feet or some other body part. Up to 10,000 people in the U.S. have the disease. And Lev says it will make the drug available later this year. The biotech company will also conduct a clinical study designed to evaluate safety, including thrombotic adverse events, efficacy and immunogenicity of higher than labeled doses of Cinryze for routine prophylaxis.

"We are ecstatic that the U.S. HAE community will finally have access to a safe and effective HAE therapy," said Anthony J. Castaldo, president of the U.S. Hereditary Angioedema Association. "Today's approval addresses a longstanding, catastrophic unmet medical need with a therapy that save lives and helps patients overcome the devastating burden posed by this debilitating and life-threatening disease."

The announcement is also good news for ViroPharma, which agreed to acquire Lev last July 15 in a $443 million deal.

- view the Lev Pharma release
- read the story from RTT News

Related Articles:
ViroPharma to buy Lev for $442M

ViroPharma to buy Lev for $442M

John Carroll — Tue, 15 Jul 2008 11:36:20 -0400

ViroPharma has forged a deal to buy Lev Pharmaceuticals--a developer focused on developing inflammatory therapies--for $442 million. The deal provides ViroPharma with Lev's Cinryze program, a late-stage therapy under FDA review as a replacement therapy for hereditary angioedema. ViroPharma will pay $2.25 per share in cash and 50 cents per share in stock.

"This transaction is consistent with ViroPharma's stated objective of broadening our portfolio of therapies for serious life-threatening conditions in selected specialty markets," commented Vincent Milano, ViroPharma's president and chief executive officer. "We are very pleased to add the expertise of Lev to our organization, and Cinryze to our growing portfolio of options for underserved patient populations with critical and urgent needs."

- check out the buyout release

Wyeth, ViroPharma drops Hep C drug

Thu, 17 Apr 2008 06:59:54 -0400

After observing serious safety problems in a Phase II trial, Wyeth and ViroPharma are dropping development of HCV-796. In August the companies halted study of the drug when the data showed elevated liver enzyme levels in some patients after eight weeks or more of therapy with HCV-796. Two study subjects experienced serious adverse events and dropped out of the trial. The decision to abandon HVC-796 wasn't a surprise to Wall Street, and analysts don't anticipate the move will have a big impact on ViroPharma's stock.

"Clearly, this is a disappointing outcome for patients suffering from this difficult disease," commented Vincent Milano, ViroPharma's president and chief executive officer. "Significant activities were undertaken to determine a clear path forward for HCV-796; however, the risk associated with potential hepatotoxicity ultimately posed too high of a hurdle to merit further development."

- check out the release
- read the report for more

Related Articles:
ViroPharma, Wyeth halt HCV study. HVC report
ViroPharma's HCV drug shows promise. ViroPharma report
Wyeth buying ViroPharma shares. Wyeth report

ALSO NOTED: Anemia drugs back in the spotlight; Biodel completes VIAject enrollment; and much more...

Fri, 04 Jan 2008 06:59:50 -0500

> The FDA has revealed two new studies that show cancer patients may be more likely to die while using Amgen's blockbuster drugs Aranesp and Epogen (also sold under the brand name Procrit by Johnson & Johnson). Report

> Biodel has completed enrollment of its two Phase III clinical trials of VIAject, an injectable meal-time insulin for use by patients with Type 1 and Type 2 diabetes. Release

> Chutes & Ladders: Pharmos has made a number of changes to its board of directors and management. Release

> Chutes & Ladders: ViroPharma has appointed Thomas F. Doyle as vice president, strategic initiatives. J. Peter Wolf has been promoted to vice president, general counsel and secretary of the Board of Directors. Release

> So far, personalized medicine isn't perfectly personalized. New data shows that diagnostic tests to determine whether women should take certain breast cancer drugs have a failure rate of up to one-quarter. Report

> At a Morgan Stanley pharma conference yesterday, Schering-Plough CEO Fred Hassan was quizzed and requizzed by investors about the Vytorin-Zetia controversy. Report

> It's increasingly apparent that some of our most-lauded new oncology agents carry pretty serious baggage: they can cause heart attacks. Report

And Finally... The pharmaceutical industry spends twice as much on marketing and promotion of drugs as it does on R&D. Report

Wyeth stumbles badly trying to develop new drugs

Mon, 13 Aug 2007 06:59:57 -0400

The analysts have been picking over Wyeth's carcass over the past few days as they assess a string of woeful developments that have left the company stripped of three of its leading drug candidates. With its hep C trial suspended at the end of last week, the analysts are raising questions about the company's ability to design trials properly. And a pair of FDA rejections hasn't helped the company's reputation one little bit. Add it all up and you see a big pharma company having a terrible time coming up with new winners to replace its fading stockpile of approved drugs. The next big milestone for Wyeth: New mid-stage data from a study for a new Alzheimer's drug being developed with Elan.

- read the report from Forbes

Related Articles:
Wyeth stock down after several setbacks. Report
ViroPharma, Wyeth halt HCV study. Report
Wyeth, Solvay handed FDA rejection. Report
Solvay expands development pact with Wyeth. Report
FDA demands more data on Wyeth's Pristiq. Report

ViroPharma, Wyeth halt HCV study

Fri, 10 Aug 2007 06:59:57 -0400

That's not all the bad news for Wyeth today. In yet another blow, the company and its partner ViroPharma have stopped dosing patients with HCV-796, a Phase II hepatitis C drug candidate. The decision follows a review by the joint safety review board of safety data accumulated to date, which shows elevated liver enzyme levels in some patients after eight weeks or more of therapy with HCV-796 with pegylated interferon and ribavirin. Two study subjects experienced serious adverse events and dropped out of the trial. The companies said they will analyze safety data in order to determine the fate of HCV-796.

- see this release

Related Articles:
ViroPharma's HCV drug shows promise. Report
Wyeth buying ViroPharma shares. Report
Four promising companies to watch. Report

Four promising companies to watch

Maureen Martino — Wed, 08 Aug 2007 10:28:10 -0400

Based on strong product pipelines, positive clinical data and impressive partnerships with big drug companies, The Motley Fool profiles four small biopharm companies that could emerge as major players--and good investments.

Array BioPharma - Array BioPharma is developing small molecule drugs to treat cancer and inflammatory disease. The company has five Phase I drugs and two more in preclinical trails. It also counts Amgen, Genentech, Takeda, Eli Lilly, and AstraZeneca among the companies that fund its drug development machine, and Array has raked in a number of milestone payments over the last few years. Because of an overabundance of early-stage assets, the company says it will out-license them to other developers over the next three years, which could help the company earn some serious cash. "Even though it is burning cash and has no compounds on the market, Array clearly has the potential to become a biotech-research powerhouse with so many novel drugs in development," notes Brian Lawler of The Motley Fool.

ViroPharma - ViroPharma and Wyeth are working on a new class of hepatitis C drug that is in Phase II testing. Early-stage testing of the drug was impressive: After 14 days of doses of HCV-796 with another therapy patients had an average viral reduction close to 100 percent. And following a rough patch a few years back, ViroPharma engineered a turn-around by acquiring profitable drug Vancocin and hiking its price; Wall Street loved the move and awarded ViroPharma accordingly. In addition to the hepatitis C program, ViroPharma is developing Maribavir, an antiviral for transplant patients that was fast-tracked last year.

Alexza - Alexza is taking a different approach to drug development. Rather than creating new drugs from scratch, the company is developing inhalable versions of generic drugs for use with its Staccato System, a device that atomizes therapeutics for inhalation. The company is formulating inhalable versions Xanax (for panic attacks), fentanyl (for pain), Loxapine (for schizophrenia) and Prochlorperazine (for migraines). The company says 200 drug compounds have been identified that may work with the Staccato System. As The Motley Fool observes, Alexza's pipeline is limited only by its budget. But the has certainly caught the attention of investors: late last year Symphony Capital Partners gave Alexza $50 million for the development of two of its drugs.

Progenics Pharmaceuticals - Progenics and its development partner Wyeth are waiting on an FDA approval for a subcutaneous version of the company's methylnaltrexone compound to treat opioid-induced constipation. An oral version--which is likely to be a blockbuster--is in Phase I trials and could hit the market as early as 2009 if all goes well. Another promising candidate is the HIV drug PRO 140; the FDA fast tracked the drug early last year. PRO 140 is a monoclonal antibody in the same class of drugs as Pfizer's newly-approved Maraviroc.

- check out the Motley Fool article for more

ALSO NOTED: Vasogen gets direction on Celacade: EndoCeutics pulls IPO; Ventana cool to bid; and much more...

Wed, 27 Jun 2007 00:01:30 -0400

> U.S. regulators have strongly suggested that Vasogen undertake a study to confirm the clinical data on Celacade before filing for approval of the heart medication. Report

> EndoCeutics has pulled its IPO, citing market conditions and a changeup in its schedule for clinical trials. The Canadian biotech is developing hormone therapies for breast cancer and endocrine-related disorders. Report

> Ventana Medical Systems has taken a cool attitude toward Roche's $3 billion takeover bid. Investors, though, showed more enthusiasm, bidding up Ventana stock 48 percent on the news from yesterday. Report

> ViroPharma's hepatitis C therapy has been fast-tracked by the FDA. Report

> Sanofi's Taxotere has been granted a priority review by the FDA for head and neck cancer. Report

> CytRx announced promising data from the six-month, open-label extension of its completed Phase IIa clinical trial with arimoclomol in ALS volunteers. Release

> As states begin to track pharma gifts to doctors, psychiatrists are increasingly coming up as top beneficiaries for pharma payments. Report

And Finally... Scientists have developed a new method using nanoparticles to deliver drugs. Report

C&L: Drakeman resigns from Medarex

Tue, 07 Nov 2006 19:01:32 -0500

Medarex CEO Donald Drakeman (photo) resigned his post as the company issued new findings in its investigation of how stock options were granted over the past 10 years.

Bradford A. Zakes was named president and CEO of ImaRx Therapeutics.

ARCA Discovery has named Richard B. Brewer president and CEO.

Meiken Krebs has been appointed president and CEO of EMD Chemicals has.

Excel Life Sciences has hired Dr. Vijai Kumar as the company's president and chief medical officer.

Acumen Pharmaceuticals has promoted Dr. William F. Goure to the post of COO.

Scott McCallister, M.D. has joined Panacos Pharmaceuticals as chief medical officer.

Invitrogen Corporation promoted Bernd Brust to the newly-created position of senior vice president of sales for Europe and the Americas.

Ciphergen Biosystems named Debra A. Young vice president and CFO.

Symphogen has named Christian Meyer, M.D., Ph.D., vice president of clinical development.

Daniel B. Soland has joined the Viropharma as its vice president and COO.

Mark Longer, Ph.D., has joined Napo Pharmaceuticals as its vice president, program planning and management.

Dynavax Technologies named Michael Ostrach as VP, chief business officer and general counsel.

Pharmacopeia has appointed Rene Belder, M.D., as vice president, clinical and regulatory affairs.

KAI Pharmaceuticals has named Dirk B. Mendel, Ph.D. as vice president of pharmacology & preclinical pharmacokinetics and pharmacodynamics.

Compugen has appointed Eli Zangvil, MD, as vice president, business development.

AtheroGenics named J. Christopher Prue, RPh to the position of vice president, regulatory affairs.

Inimex Pharmaceuticals has named Dr. K. Jeffry Wilson as vice president of product development.

BioInformatics has appointed Rowena Roberts, Ph.D. as director of marketing and sales.

Aradigm Corporation has appointed John M. Siebert, Ph.D. to the board of directors.

King Pharmaceuticals named Philip A. Incarnati to the company's board of directors.

MacuSight has named Brian C. Cunningham to its board of directors.

SpeciGen has named David Goldsteen, MD, to its board of directors.

BioXell announced that Thomas Szucs, member of its board of directors, has been appointed chairman of the board, replacing Michael Steinmetz who will remain on the board.

Ikonisys has appointed J. Timothy Corcoran to its board of directors.

National Stem Cell Holding announced that Michael J. Shamblott, Ph.D., a founding member of the Johns Hopkins University School of Medicine's Institute for Cell Engineering, has been named the company's chief scientific advisor.

ALSO NOTED: Swiss approve Lucentis; ViroPharma shares buoyed by hep C data; and much more...

Mon, 28 Aug 2006 20:00:50 -0400

> Novartis has announced that Switzerland has approved Lucentis for age-related macular degeneration, marking its first European approval for the drug. The FDA approved Lucentis two months ago. Novartis says it will start supplying the drug in September. Report

> ViroPharma shares were buoyed by positive results from an early trial of its drug for hepatitis C. After 14 days of doses of HCV-796 with another therapy patients had an average viral reduction close to 100 percent. Plans for Phase II are underway. Report

> Eli Lilly and India's Suven Life Sciences will collaborate on the preclinical development of new therapies for CNS disease. Suven gains upfront and milestone payments to identify new compounds. Report

> Bausch & Lomb has expanded its development pact with Talecris Biotherapeutics, gaining development rights for rPlasmin, a recombinant derivative of the human blood component plasmin that helps to dissolve blood clots. Bausch & Lomb is enlisting volunteers for an early-stage trial of rPlasmin. Report

> The FDA has approved a generic version of the injectable antibiotic Cipro. Report

> Purdue Pharma and Teva Pharmaceuticals USA have agreed to end their lawsuit concerning certain Purdue Pharma patents on OxyContin Tablets. Release

And Finally… St. Jude's Dr. Mary Relling has emerged as a leading advocate of genetic testing for providing the right drug prescription. Article

SPOTLIGHT: Wyeth buying ViroPharma shares

Sun, 13 Aug 2006 20:01:33 -0400

Wyeth will buy $10 million in ViroPharma shares after the two collaborators achieved proof-of-concept stage for an experimental hepatitis C therapy. Preliminary data from Phase I should be available by the end of August. Report

ALSO NOTED: Salix hopes to delay generic; ViroPharma raises new generic complaint; and much more...

Tue, 04 Jul 2006 20:00:50 -0400

> Salix Pharmaceuticals is hoping it can delay a generic competitor to its most lucrative pharmaceutical. Report

> ViroPharma has added a fresh set of complaints to the objections being raised against a generic competitor to its antibiotic Vancocin. The drug developer says that the agency should require clinical studies to establish bioequivalence. Allowing laboratory work alone would significantly reduce the time it would take to gain approval. Report

> IVREA Pharmaceuticals has raised $11 million in new venture funds. Report

> Abbott Laboratories and AstraZeneca have inked a deal to develop a combinational therapy for cholesterol. Report

> Shares of Tercica jumped on the news that a federal court has ruled that its patents on Increlex are valid. Report

> Symphony Medical has begun a Phase II trial of a therapy for post-operative atrial fibrillation. Release

And Finally... Ian Wilmut, a leading expert on cloning, notes that the absence of a cloned primate underscores just how difficult it would be to clone a human. Report

ALSO NOTED: Nektar gains fast track for lung infection drug; Vertex reports positive hep C data; and much more...

Sun, 21 May 2006 20:00:50 -0400

> Nektar Therapeutics was given a fast-track designation for its lung infection prevention drug. Report

> Vertex announced that all 12 patients in a mid-stage trial of its VX-950 hepatitis C therapy showed no detectable signs of the virus after 28 days of therapy. Report

> ViroPharma announced that HCV-796, in development with Wyeth, cut levels of the hepatitis C virus by 97 percent in a small Phase I trial. Report

> CombinatoRx has released positive data for its mid-stage trial of Crx-102 for patients with periodontitis. Report

> Cell Genesys reports that an early-stage trial demonstrated that its experimental therapy, CG-0070, was safe and may have anti-tumor activity. Report

> A new study presented at the scientific meeting of the American Psychiatric Association has identified five predictors of bipolar disease. Researchers concluded that significant risk factors of bipolar disorder among patients already diagnosed with major depression were anxiety, feelings of people being unfriendly, family history of bipolar disorder, a recent diagnosis of depression and legal problems. Release

> Repros Therapeutics provided an update for its ongoing clinical studies. Release

> Consumer groups are asking the FDA to do a better job at policing nanotechnology. Report

> Alexza Pharmaceuticals has launched a Phase I trial of an experimental pain therapy. Release

And Finally… The search for an HIV vaccine has moved overseas amid a storm of controversy. Article

ALSO NOTED: Biogen Idec, Elan start new Tysabri study; Watson to divest manufacturing facility in AZ; and much more...

Wed, 29 Mar 2006 19:00:50 -0500

> Watson Pharmaceuticals will divest its injectable manufacturing facility located in Phoenix. If Watson can't find a buyer, the company will close the facility by the end of the second quarter in 2007. Release

> Biogen Idec and Elan have dosed the first patients in a safety extension study program of Tysabri, the multiple sclerosis treatment that was pulled from the market last year due to safety concerns. Earlier this month an FDA expert committee recommended returning Tysabri to market, but the FDA delayed the decision. The companies said they expect action by the FDA regarding Tysabri on or before June 28. Report

> ViroPharma announced positive preliminary results from a Phase II study of maribavir, an oral antiviral drug candidate currently being developed to inhibit cytomegalovirus reactivation in transplant patients. Report

> Galapagos' service division BioFocus has entered into a three-year alliance Arthrogen. The companies will focus on discovering targets for gene therapy applications in rheumatoid arthritis. Release

> Eisai and DNAVEC, a venture company, have inked a deal on drug discovery research for vaccine therapy for Alzheimer's Disease. Release

> Kosan Biosciences announced the pricing of an offering of 5 million shares of common stock at a price of $5 per share. Release

> PTC Therapeutics has been granted Fast Track designation by the FDA for PTC124, a therapy for Duchenne muscular dystrophy (DMD). The drug received Orphan Drug status in 2004 is now in Phase II trials for both DMD and cystic fibrosis. Results are anticipated later this year. Release

> Genentech Biogen Idec have submitted an sBLA for Rituxan in low-grade or follicular CD20-positive B-Cell Non-Hodgkin's lymphoma. Report

> Chutes & Ladders: Dr. Frank M. Armstrong has been appointed president and CEO of CuraGen. Report

And Finally... A Jello-like material combined with stem cells could proved to be a winning combination for spinal injuries. Article

ALSO NOTED: ViroPharma drug gains fast track; Nabi touts trial data; and much more...

Mon, 06 Feb 2006 19:00:50 -0500

> The FDA has granted ViroPharma fast track status for its transplant antivirus drug maribavir. The therapy is in mid-stage trials with the Exton, PA-based developer expected to release data by the end of this quarter. Report

> New River Pharmaceuticals has pocketed a $50 million milestone payment from Shire based on the Phase I/II data for its experimental pain drug NRP290. Release

> Nabi Biopharmaceuticals announced positive data from Phase I studies of the company's S. epidermidis PS-1 vaccine and its S. aureus Type 336 vaccine. Release

> Roche says it will halt sales of the HIV drug Fortovase in favor of another, more convenient medication. Report

> Ciphergen has inked a research pact with Sanofi-Aventis to seek biomarkers for a pre-clinical drug efficacy study in the field of oncology. Release

> Optimer's lead antibiotic therapy is headed into a Phase IIb/III trial for Clostridium difficile-associated diarrhea. Release

And Finally... New research indicates that your cardiovascular risk factors at age 50 will have a major impact on your life expectancy. Report

ALSO NOTED: Genetic mutation found for Parkinson's; Rigel to receive milestone payment;and much more...

Wed, 25 Jan 2006 19:00:50 -0500

> Researchers have discovered a genetic mutation that accounts for more than one-in-five cases of Parkinson's for Arabs, North Africans and Jews. This is particularly surprising as genetics was not thought to play a major role in the disease. Article

> Altus Pharmaceuticals has priced its IPO of 7 million shares at $15 a share. Release

> Rigel Pharmaceuticals of South San Francisco will receive a $5 million milestone for the advancement of its cancer therapy, R763. Release

> Par Pharmaceuticals has divested FineTech Labs, which employs 42 people in Israel. Release

> The Dutch biotech Pharming Group has raised €17.1 million to develop its recombinant human C1 inhibitor. Release

> Pfizer has sued Dainippon Sumitomo Pharma over a hypertension drug, demanding the return of any data for the drug and a cessation to any marketing efforts. Report

> Callisto Pharmaceuticals has signed an agreement with The University of Texas M.D. Anderson Cancer Center for the licensing of a new class of cancer drugs called Degrasyns for development as anti-cancer agents. Release

> ViroPharma is moving to eliminate its long-term debt. Release

> Amgen and Genentech have entered into a licensing contract for antibody patents. Release

And Finally… Racial differences play a large role in determining who gets lung cancer, according to researchers. Blacks are 55 percent more likely than whites to suffer from the disease. Article

C&L: Genaera makes CEO's job permanent

Tue, 24 Jan 2006 19:01:32 -0500

Genaera's board of directors has decided to make John 'Jack' L. Armstrong, Jr. its CEO and president. Armstrong was appointed interim CEO several weeks ago.

SkyePharma Chairman Ian Gowrie-Smith resigned in the face of a shareholder revolt.

Immtech International has named Eric L. "Rick" Sorkin as CEO.

MicroIslet has appointed James R. Gavin III, M.D., Ph.D., as its interim president and CEO.

Celsion founder Augustine Cheung has acquired a subsidiary of the company and will leave to operate it.

Exagen Diagnostics has named Robert Mignatti as president and COO.

Nektar Therapeutics has named Louis Drapeau as senior vice president, finance and CFO.

Alimera Sciences has named Richard S. Eiswirth as the company's CFO.

Axcan Pharma has appointed Steve Gannon as CFO and senior vice president, replacing Jean Vezina who was named vice president of finance.

Targeted Genetics named David J. Poston as vice president, finance, CRO and treasurer.

Cardium Therapeutics has appointed Randall W. Moreadith, M.D., Ph.D., as executive vice president and chief medical officer.

PerkinElmer has named Dr. Aaron Geist as vice president, business development.

ViroPharma has made the following supplements to management: Vincent Milano, ViroPharma's vice president and CFO, will also act as the company's COO; Clayton Fletcher has been promoted to vice president, business development; Thomas Lembck has been promoted to vice president, information technology; Stephen Villano, M.D., has been promoted to vice president, clinical research and development; and Debra Gayda, Ph.D., has been appointed as vice president, regulatory affairs.

ZIOPHARM Oncology has appointed Robert Morgan, MS, JD, as vice president of regulatory affairs and quality, and contract counsel.

BioXell has promoted Meenu Chhabra to chief business officer.

Xenomics has appointed Dr. Mark O'Hara as director of product development.

454 Life Sciences named Katherine Webster as vice president for measurement services center sales.

WuXi PharmaTech announced the appointment of Dr. Angela Wong as vice president of service biology.

Pfizer has named Amal Naj vice president, investor development and strategy. He succeeds Jim Gardner, who will retire in April after 29 years of service to Pfizer.

Blaine Pharmaceuticals has made several new hires: Michael Saig was named to its team as director of national accounts and Bethany Flick was named marketing associate.

Intranasal Therapeutics has formed a Scientific Advisory Board chaired by Jordan L. Cohen, Dean of the College of Pharmacy at the University of Iowa. Others on the board are: Paul Ashton, Ph.D; Jacqueline A. French, M.D.; Sveinbjorn Gizurarson, Ph.D.; Sam R. Sharar, M.D.; and Daniel P. Wermeling, Pharm.D.

Advantage Software has added Nicholas Allen, associate director, business development for PharmaNet, to its board of advisors.

OncoMethylome Sciences has elected Philip S. Schein, M.D., F.R.C.P to its board of directors.

Targanta Therapeutics has elected William W. Crouse to its board of directors.

ViroPharma's stock falls in face of generic competition

Thu, 10 Nov 2005 19:01:35 -0500

Despite positive early results for ViroPharma's hepatitis C treatment, the company's stock fell sharply yesterday. The drop was due to an announcement that Akorn and an Indian drug manufacturer might develop a generic version of Vancocin. ViorPharma bought Vancocin, an antibiotic, from Lilly last year. The drug had already lost patent protection when ViroPharma made the purchase.

- see this article from AP

SPOTLIGHT: ViroPharma's HCV drug shows promise

Wed, 09 Nov 2005 19:01:33 -0500

Preliminary results for ViroPharma's phase I hepatitis C orally administered drug HCV-796 demonstrated antiviral effects in adult patients with chronic hepatitis C infection. Release

Profile: ViroPharma mounts comeback following Vancocin buyout

Tue, 30 Aug 2005 20:01:37 -0400

Floundering badly following the FDA's 2002 rejection of its lead drug candidate, small Philadelphia-based biotech ViroPharma has mounted a comeback. A new management team has reorganized, acquired a profitable drug in Vancocin and hiked its price by 47 percent, and is in Phase II with a drug it licensed from GlaxoSmithKline. One or two other deals are also in the works. The Philadelphia Inquirer examines ViroPharma's comeback strategy.

- read this article from the Philadelphia Inquirer for more